

**Composition :** Sitagliptin+Metformin; (50mg+500mg) & (50mg+1000mg) Tablet.

**Indications :** It is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of sitagliptin and metformin as separate tablets.

**Dosage and administration :** The dosage should be individualized on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. This medicine should generally be given twice daily with meals, With gradual dose escalation, to reduce the gastrointestinal (GI) side effects due to metformin. The recommended starting dose in patients not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily. The starting dose in patients already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and the dose of metformin already being taken. Or, as directed by total daily dose and the dose of metformin already being taken. Or, as directed by the registered physician.

**Contraindications :** It is contraindicated in-patient with known hypersensitivity to the drug, Renal disease or renal dysfunction, and acute or chronic metabolic acidosis, including diabetic ketoacidosis.

**Side effects :** Vomiting, gastrointestinal

## Sliptin-M Tablet

pain, diarrhea, allergic skin reactions, e.g. pruritus, erythema, urticaria, and or maculopapular eruptions, may occur.

**Use in pregnancy and lactation :**

**Sliptin-M** has been assigned to pregnancy category B by the FDA.

**Drug interactions :** Drugs that are highly protein bound, such as anti-inflammatory drugs, salicylates, sulfonamides, chloramphenicol, probenecid monoamine oxidase inhibitors, and B- adrenergic blocking agents may cause hypoglycemia. Thiazides, and other diuretics, corticosteroids, phenothiazine, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid and isoniazid tend produced hyperglycemia.

**Precautions :** Do not use the combination of Sitagliptin & Metformin in patients with hepatic disease. \* Before initiating the combination and at least annually thereafter assess renal function and verify as normal. \* May need to discontinue the combination and temporarily use insulin during periods of stress and decreased intake of fluids and food as may occur with fever, trauma, infection or surgery.

**Packing :**

**Sliptin-M 500 :** 2x7's tablets in blister pack.

**Sliptin-M 1000 :** 2x7's tablets in blister pack.